
Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients
Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020.
These data, which build upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to consistently inform optimal treatment planning, highlight Agendia’s many trials in progress that will ultimately impact patient treatment and outcomes.
Specific data selected for poster spotlight discussions include:
- BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
Authors: Krop, I., et al.
Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
Poster #: PD3-01
- 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
Authors: Whitworth, P., et al.
Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
Poster #: PD9-01
In addition, Laura van’t Veer, PhD, co-founder and Chief Research Officer at Agendia, will be giving an oral presentation on an abstract entitled “How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status.”
“The MammaPrint and BluePrint assays give patients with breast cancer and their healthcare providers the precise information they need to determine which treatment approach is the most targeted and effective for their situation,” says William Audeh, MD, MS, Chief Medical Officer at Agendia. “Our continued efforts to identify and understand the biologic drivers of breast cancer in large patient populations have also enabled us to look within these to study unique subsets of people, and to offer additional important insights, as we continue to expand knowledge in breast cancer and build a library of data that will be of benefit to patients.”
Following are details of additional Agendia abstracts that have been accepted for SABCS 2020:
- How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
Authors: van’t Veer, L.J., et al.
Session: General Session 4 | Friday, December 11, 2020 | 8:45am – 11:30am CST
Poster #: PS6-01
Presentation #: Oral Presentation GS4-11 | Presentation 11:15am-11:25am CST | Live Q&A Session 11:25am-11:30am CST
- Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
Authors: Whitworth, P., et al.
Session: Poster Session 4
Poster #: PS4-04
- The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.
Authors: Noordhoek, I., et al.
Session: Poster Session 6
Poster #: PS6-06
- Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
Authors: McKelley, J., et al.
Session: Poster Session 6
Poster #: PS6-19
- MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer
Authors: Blumencranz, P.W., et al.
Session: Poster Session 6
Poster #: PS6-41
- Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients
Authors: Sharma, D., et al.
Session: Poster Session 7
Poster #: PS7-68
- Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients
Authors: Chen, M., et al.
Session: Poster Session 7
Poster #: PS7-69
- Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients
Authors: Crozier, J., et al.
Session: Poster Session 14
Poster #: PS14-11
- Differential gene expression in Luminal-type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
Authors: Lesnikoski, B., et al.
Session: Poster Session 18
Poster #: PS18-03
- Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
Authors: Kaklamani, V.G., et al.
Session: Poster Session 18
Poster #: PS18-05
- The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
Authors: Lee, L., et al.
Session: Ongoing Trials Posters
Poster #: OT-12-01
These data underscoreAgendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
Please follow us on our Twitter, Facebook and LinkedIn pages for unique content we will be sharing throughout SABCS.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens with results in as little as 5-7 days to inform pre- and post-operative treatment decisions. For more information on our assays and our ongoing trials, please visit www.agendia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005474/en/
Contact information
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo